Abstract Molecular imaging of human epidermal growth factor receptor type 2 (HER2) expression has drawn significant attention because of the unique role of the HER2 gene in diagnosis, therapy and prognosis of human breast cancer. In our previous research, a novel cyclic 2-helix small protein, MUT-DS, was discovered as an anti-HER2
Introduction
The epidermal growth factor receptor (EGFR) family is a group of receptor tyrosine kinases (RTKs) which have been shown to be key regulators of many cellular events, making them important targets in cancer research (Ciardiello and Tortora 2008; Yarden and Shilo 2007) . Of the four members of the EGFR family, human epidermal growth factor receptor type 2 (HER2) is a well-established tumor biomarker over-expressed in a wide variety of cancers including breast, ovarian, lung, gastric, oral and urogenital cancers (Glisson et al. 2004; Mitra et al. 1994; Swanton et al. 2006; Yeh et al. 1999; Engel and Kaklamani 2007; Nanda 2007) . HER2-targeted therapy using Herceptin and/or combination with conventional therapeutic regimens has shown significant benefits in breast cancer patients (Harries and Smith 2002; Lazaridis et al. 2008; Tokuda et al. 2009 ). HER2 has great value as a molecular target for therapeutic intervention. Moreover, HER2 is an important prognostic indicator of cancer patients (Gravalos and Jimeno 2008; Ferretti et al. 2007; Serrano-Olvera et al. 2006) .
Antibody-based radionuclide imaging has been extensively investigated to monitor HER2 status and relevance to therapy. Radiolabeled Herceptin has shown promise in noninvasive evaluation of HER2 expression in vivo (Niu et al. 2009; Tang et al. 2005; Dijkers et al. 2009; SmithJones et al. 2004) . However, Herceptin is a large protein and may not be ideal for PET imaging because of its slow clearance and tumor-targeting ability. Affibody protein which binds to a different epitope on HER2 may be a more suitable imaging candidate for the purpose of in vivo monitoring of HER2 expression McLarty et al. 2009a) . Additionally, Affibody proteinbased molecular imaging technology has shown great advantages over antibodies because of the short blood circulation and rapid and excellent tumor uptake of Affibody molecules (Tolmachev 2008) . Affibody molecules are engineered non-immunogenic small proteins with 58-amino acid residues (*7 kDa) and a 3-helix bundle structure (Nygren 2008; Nygren and Skerra 2004; Tolmachev et al. 2007a ). HER2-binding Affibody molecules with picomolar affinity have been identified and investigated as therapeutic and imaging agents for HER2-overexpressing malignant tumors McLarty et al. 2009b; Kramer-Marek et al. 2009; Wallberg et al. 2009; Tran et al. 2007; Tolmachev et al. 2006 Tolmachev et al. , 2009 Orlova et al. 2006; Cheng et al. 2008; Ahlgren et al. 2009 ). In our previous studies, we have found that of the various anti-HER2 Affibody protein constructs available (monomeric vs. dimeric), the smaller ones performed substantially better in vivo in terms of tumor uptake as well as better clearance (Cheng et al. 2008) . Therefore, to make even smaller version of Affibody constructs, one a-helix (helix 3) that is not directly responsible for receptor recognition in the Z HER2:342 was truncated, while preserving the binding domain that is composed of surface-exposed amino acid residues in the two a-helices (helix 1 and 2) bundles of Affibody ( Fig. 1) ). A library of such 2-helix protein constructs with *4.6 kDa molecular weight (MW) was chemically synthesized and evaluated. Several disulfide bridge-constrained 2-helix constructs with high HER2 affinity [low nanomolar (nM)] were successfully identified ).
The small size and high HER2-binding affinities of these 2-helix proteins encouraged us to further evaluate their potential use for in vivo molecular imaging of tumors. One cyclic 2-helix small protein with 5 nM HER2-binding affinity was then selected and conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to obtain a bioconjugate DOTA-MUT-DS [sequence: VENK (homoC)NKEMR NRYWEAALDPNLNNQQKRAKIRSI YDDP(homoC)-NH 2 , a disulfide bridge was formed between two homo-cysteine residues]. In previous research, PET radionuclides with relative short half-life, 68 Ga (t 1/2 = 67.7 min) and 18 F (t 1/2 = 109.8 min) were used to label MUT-DS for HER2 PET imaging (Ren et al. 2009; Miao et al. 2011 ). In order to fully study the in vivo behavior of 2-helix small protein and demonstrate that it could be a robust platform for labeling with a variety of radionuclides for different applications, in this study, MUT-DS was further radiolabeled with (t 1/2 = 12.7 h) or 111 In (t 1/2 = 2.8 d) and evaluated for in vivo targeting of HER2-positive tumor in mice.
Materials and methods

General
The anti-HER2 Affibody molecule Z HER2:477 was purchased from Affibody AB (Bromma, Sweden). DOTA-tri-tert-butyl ester was obtained from Macrocyclics Inc. (Cheng et al. 2008 ).
Synthesis of DOTA-MUT-DS
Synthesis of the cyclic 2-helix small protein, DOTA-MUT-DS, was the same as described in our previous reports ). Briefly, peptide was synthesized using standard solid-phase peptide synthesizer (Fmoc chemistry). Then the linear peptide was cyclized by I 2 oxidation of the two homo-cysteines. Both crude linear and cyclic peptides were purified by a reversed-phase preparative HPLC with a protein and peptide C4 column (Vydac, Hesperia, CA, USA). The identity of the target peptides was confirmed by matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MALDI-TOF-MS, model: Perseptive Voyager-DE RP Biospectrometer) (Framingham, MA, USA) or an electrospray ionization time of flight mass spectrometer (ESI-TOF-MS, model: JMS-T100LC) (JEOL, Tokyo, Japan). In) , respectively. The radiolabeled complex was then purified by a PD-10 column (GE Healthcare, Piscataway, NJ, USA). The product was washed out by phosphate-buffered saline (PBS) and passed through a 0.22 lm Millipore filter into a sterile vial for in vitro and animal experiments. Radioanalytical HPLC was used to analyze the purified 64 Cu or 111 In-labeled-DOTA-MUT-DS. The flow rate was 1 mL/min, with the mobile phase starting from 95% solvent A (H 2 O/0.1%TFA) and 5% solvent B (CH 3 CN/0.1%TFA) (0-3 min) to 35% solvent A and 65% solvent B at 33 min, then going to 15% solvent A and 85% solvent B (33-36 min), maintaining this solvent composition for another 3 min (36-39 min) and returning to initial solvent composition by 42 min.
Serum stability 64 Cu/ 111 In-DOTA-MUT-DS (370 kBq) in 50 lL of PBS was added to 500 lL of mouse serum (Sigma, St. Louis, MO, USA). After incubation at 378C for 1 h, the solution was analyzed by thin layer chromatography (TLC). The developing solution was 50% H 2 O/50% CH 3 CN.
SKOV3 tumor xenografts
SKOV3 cells were harvested and 3 9 10 6 cells were diluted in 100 lL of PBS then subcutaneously implanted into the right upper shoulder of 6-to 7-week-old female nu/ nu mouse (Charles River, Wilmington, MA, USA). Tumors were allowed to grow to a size of 500-750 mg (2-3 weeks), and the tumor-bearing mice were subjected to in vivo biodistribution and imaging studies. Biodistribution studies SKOV3 tumor-bearing mice (n = 3 for each group) were injected with 64 Cu-DOTA-MUT-DS (0.69-1.01 MBq, 18.7-27.4 lCi, 0.58-0.86 lg) or 111 In-DOTA-MUT-DS (0.26-0.3 MBq, 7-8 lCi, 0.12 lg) through the tail vein and killed at 1, 4 and 20 h post-injection (p.i.). For a blocking study, another group of SKOV3 tumor-bearing mice (n = 3) were co-injected with 300 lg unlabeled Z HER2:477 in PBS containing 2% bovine albumin serum (Invitrogen, Carlsbad, CA, USA) and killed at 4 h p.i.. Tumor and normal tissues of interest were excised and weighed, and their radio activity was measured in a Wallac 1480 automated counter (Perkin Elmer, MA, USA). The radioactivity uptake in the tumor and normal tissues was expressed as a percentage of the injected radioactive dose per gram of tissue (% ID/g). The ratio of tumor to blood (T/B) and tumor to muscle (T/M) were determined based upon % ID/g.
MicroPET imaging
PET imaging of tumor-bearing mice was performed on a microPET R4 rodent model scanner (Concord Microsystem, Knoxville, TN). The mice bearing SKOV3 tumors were injected with 64 Cu-DOTA-MUT-DS (1 MBq, 27 lCi, 0.9 lg) via the tail vein. For another group of mice bearing SKOV3 tumors (n = 3), each mouse was coinjected with the same activity of probe and 300 lg of non-radiolabeled Z HER2:477 . At different times p.i. (0.5, 1, 2, 4 and 20 h), the mice were anesthetized with 2% isofluorane and placed in the prone position and the center of the filed of view of microPET. The 5-min static scans were obtained and the images were reconstructed by a two-dimensional ordered-subset expectation maximum (OSEM) algorithm.
Statistical methods
Statistical analysis was performed using the Student's t test for unpaired data. A 95% confidence level was chosen to determine the significance between groups, with P \ 0.05 being significantly different. In-DOTA-MUT-DS remained labeled product after 1 h incubation at 37°C.
Results
Chemistry
Biodistribution studies
Biodistribution results for 64 Cu-DOTA-MUT-DS at 1, 4 and 20 h p.i. were summarized in Table 1 . Rapid and high activity accumulation in the SKOV3 tumors was observed at early time points (4.66 ± 0.38%ID/g at 1 h p.i.). Tumor uptake slightly reduced to 3.34 ± 0.89%ID/g at 4 h; then the activity was slowly washed out from the tumor and reached 2.13 ± 1.11%ID/g over 20 h ( Table 1) . The blood uptake was 1.54 ± 0.18%ID/g at 1 h p.i., while it remained for 1.1 ± 0.02%ID/g at 20 h p.i. The tumor to blood ratio could attain around 3.05 ± 0.3 at 1 h p.i. and decreased over 20-h periods. While tumor to muscle ratio continued to increase from 3.48 ± 0.53 at 1 h p.i. to 5.56 ± 2.15 at 4 h p.i. Very high renal uptake and was found for the probe with 254.2 ± 19.1%ID/g at 1 h and the activity was washed out and reached 24.97 ± 8.03 at 20 h p.i. The liver uptake was 27.76 ± 6.4 and 13.39 ± 3.65%ID/g at 1 and 20 h p.i., respectively ( Table 1) . Specificity of the probe was then examined in a separate group of mice (n = 3); the co-injection of 300 lg of unlabeled Z HER2:477 significantly reduced the tumor uptake from 3.34 ± 0.89 to 1.76 ± 0.12%ID/g at 4 h p.i. (P \ 0.05), with 48.2% inhibition (Fig. 2) . Though liver uptake also decreased from 20.25 ± 5.77 to 12.27 ± 2.2 while kidney uptake increased from 137.7 ± 17.3 to 214.2 ± 48.5 at 4 h p.i., they were not significantly different compared with nonblocking group (P [ 0.05) (Table 1) .
Interestingly, in vivo biodistribution of 111 In-DOTA-MUT-DS showed some difference from the 64 Cu-labeled one ( Table 2 ). The tumor uptake reached comparable level as that of 64 Cu-DOTA-MUT-DS, but the blood clearance was faster (1.06 ± 0.13%ID/g at 1 h while only 0.18 ± 0.02%ID/g at 20 h p.i.) when compared with 64 Cu-DOTA-MUT-DS. Thus the tumor to blood ratio for 111 In-DOTA-MUT-DS reached 9.57 ± 0.93 at 20 h p.i. Both the liver and intestine uptakes for 111 In-DOTA-MUT-DS were significantly lower than that of 64 Cu-DOTA-MUT-DS at all time points (P \ 0.05).
MicroPET imaging
Decay-corrected coronal microPET images of a mouse bearing SKOV3 tumor at 0.5, 1, 2, 4 and 20 h and a mouse injected with the probe and unlabeled Z HER2:477 are shown in Figs. 3, 4 , respectively. For 64 Cu-DOTA-MUT-DS, SKOV3 tumor was clearly visualized with good tumor-tobackground contrast from 0.5 to 20 h p.i. Liver activity was observable while high activity accumulation was particularly obvious in the kidney region, which was consistent with the findings from the biodistribution study. Furthermore, the co-injection of unlabeled Affibody Z HER2:477 significantly reduced the uptake of 64 Cu-DOTA-MUT-DS in the tumor, resulting in a much lower tumor to background contrast in vivo (Fig. 4) .
Discussion
A variety of radiolabeled Affibody molecules have been successfully demonstrated to be promising molecular probes for imaging HER2 expression in living subjects (Orlova et al. 2006 McLarty et al. 2009 ). 18 F-labeled 3-helix Affibody dimer (Z HER2:477 ) 2 and monomer Z HER2:477 were recently evaluated in tumor-bearing mice by our group (Tolmachev et al. 2007 ). It was found that monomer showed much better in vivo pharmacokinetics such as higher tumor uptake and faster blood clearance than that of dimer, though it had lower in vitro HER2 binding affinity (Nygren and Skerra 2004) . In this research, a cyclic 2-helix Affibody analog MUT-DS was selected for DOTA conjugation, radiolabeling with radiometals ( 64 Cu or 111 In) with longer half-life and microPET imaging. The potential advantages expected for smaller protein constructs include easy library generation for screening, economic viability, potentially low immunogenic potential, high specific tumor-targeting ability, fast tumor extravasation, and reasonable tumor accumulation and retention. Cu-DOTA-MUT-DS at 4 h p.i. (n = 3 for each group) 64 Cu-DOTA-MUT-DS. 111 In has an even longer half-life of 68 h and has been extensively utilized as a surrogate isotope for 90 Y or 177 Lu, both of which are suitable for radionuclide therapy (Ellisonet al. (2010); McDevitt et al. 2007) . With all these radiolabels, we may comprehensively evaluate 2-helix small protein as a novel platform for in vivo targeted imaging of HER2 expression.
It was found that 2-helix probes still preserved good in vivo tumor-targeting ability. The 64 Cu-DOTA-MUT-DS displayed 4.66 ± 0.38, 3.34 ± 0.89 and 2.13 ± 1.13%ID/ g SKOV3 tumor uptake at 1, 4 and 20 h, respectively (Table 1 ). The slightly higher tumor uptake at 1 h than that of 4 h suggests the rapid tumor-targeting ability of 2-helix probe, likely due to the small size of the protein. Meanwhile, compared with tumor uptake at 1 h, 46% of radioactivity still remained in tumor at 20 h p.i., indicating good tumor retention for 64 Cu-DOTA-MUT-DS. Furthermore, the success of inhibition of the probe tumor uptake using the cold Affibody molecule Z HER2:477 (3.34 ± 0.89 vs. 1.76 ± 0.12%ID/g, 4 h p.i., P \ 0.05) proved the in vivo tumor-targeting specificity of the probe (Fig. 2) . In addition, reasonable tumor-to-blood and tumor-muscle ratios (3.05 and 3.48) were attained at 1 h p.i., suggesting 64 Cu-DOTA-MUT-DS can be used for tumor imaging. Lower tumor-to-blood ratio (1.36) was achieved at 20 h, mainly because of the relatively high activity residue in the blood. But good tumor-to-muscle ratio (3.72) at 20 h still warrants the good tumor imaging quality (Fig. 3) . High uptake in liver and moderate uptake in intestines were also observed, indicating that the probe was partially cleared through hepatobiliary system. This is also caused by the low in vivo stability of 64 Cu-DOTA complex (Boswell et al. 2004) . The in vivo tumor imaging ability of 64 Cu-DOTA-MUT-DS was further examined using SKOV3 tumor mice and microPET imaging. Excellent tumor to background contrast was obtained as early as 30 min after intravenous injection of the probe (Fig. 4) , confirming the fast tumor targeting and clearance of the 2-helix protein.
Good tumor localization and contrast were also observed at 20 h p.i.; consistent with the finding obtained in biodistribution study. Similarly, SKOV3 tumors were not visible in the mice with co-injection of cold Affibody molecules (Fig. 4) , suggesting good specificity of the probe in vivo.
DOTA is the most commonly used chelator for radiometal labeling. However, considering of some potential limitations of using DOTA as chelators for 64 Cu labeling, we also used 111 In to label the small protein and tested the biodistribution of 111 In-DOTA-MUT-DS (Boswell et al. 2004; Prasanphanich et al. 2007) . Different from what we observed for 64 Cu-DOTA-MUT-DS, 111 In-DOTA-MUT-DS showed much lower liver and intestine uptakes in vivo. This is likely resulted from the higher stability of 111 Inlabeled peptides. When compared with 64 Cu-DOTA-MUT-DS, the blood clearance of 111 In-DOTA-MUT-DS was faster; thus, a higher tumor to blood ratios could be attained at later time points. For example, the tumor to blood ratio for 111 In-DOTA-MUT-DS was about 9.57 at 20 h, which ensures the feasibilities of using 111 In-DOTA-MUT-DS for single photon emission computed tomography (SPECT) imaging of HER2 expression in vivo. 111 In is a surrogate radionuclide for beta emitter 90 Y as well as emits both therapeutic Auger and internal conversion electrons (Capello et al. 2003) ; thus, radionuclide therapeutic potential of MUT-DS could also be evaluated when using 111 In as a radiolabel. In this study, the 111 Inlabeled MUT-DS shows good tumor uptakes and retention; thus, it does have potential for HER2-targeted radionuclide therapies. Some other strategies such as including a human serum albumin (HSA)-binding domain or HSA itself to 2-helix protein were also under investigation to optimize the radiocomplexes for radionuclide therapy purpose (Andersen et al. 2011; Tolmachev et al. 2007b) .
Many reports have demonstrated that radiometal-labeled 3-helix Affibody molecules displayed high kidney uptake and retention, which may limit their applications for tumor imaging and treatment, especially when Affibody is labeled with therapeutic radionuclides (Tolmachev et al. 2006 (Tolmachev et al. , 2007b Wallberg and Orlova 2008; Ekblad et al. 2008) . Very high kidney uptake was also observed for 64 Cu or 111 In-DOTA-MUT-DS. The extremely high kidney uptake value for both radioconjugates suggested that the clearance of the radiometal-labeled 2-helix protein is mainly through kidney-urinary system. Our results indicate that the problem caused by high kidney uptake of Affibody protein could not be alleviated by simply reducing the size of the protein through truncating one alpha-helix (SANLLAEAKKLNDAQAPK). It is most likely that the amino acid residues presenting in the helix 1 and 2 of the Affibody (Fig. 1) and the DOTA chelator contribute to the high kidney uptake of radiometal-labeled Affibody molecules. More studies are needed to understand the mechanism of the globular filtration and tubular reabsorption towards this particular class of proteins, in order to further optimize the probe for clinical translation. Several strategies established in the peptide/antibody-based imaging field may also be explored to reduce the high kidney uptake. First, different amino acid sequences, linker systems and chelators can be used to modulate the surface charge, lipophilicity and binding affinity of the protein; second, co-injection of cold amino acids such as lysine; and third, nonresidulized radioisotopes such as radiohalogens can also be used (Tolmachev et al. 2007b; Ekblad et al. 2008; Gotthardt et al. 2007 ).
Conclusion
A 2-helix Affibody analog has been successfully synthesized. Radiolabeled 2-helix small protein shows good in vitro stability and in vivo tumor-targeting ability. Biodistribution and microPET imaging studies further demonstrate that 64 Cu/ 111 In-labeled 2-helix DOTA-MUT-DS are promising molecular probes for imaging HER2-positive tumor in living mice. Strategies to further optimize the biodistribution of the 2-helix proteins and 2-helix molecules against other targets are also under active investigation in our laboratories. Overall, the 2-helix small protein scaffold holds great promise as a novel platform that will likely be used for many imaging and therapy applications. 
